Burosumab-twza 30 mg in 1 mL Injection
RxNorm 2043876
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 2043876 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: burosumab-twza 30 mg in 1 mL Injection.
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
SCDPrescribable
Semantic Clinical Drug (SCD):
1 mL burosumab-twza 30 mg/ML Injection
(Atom ID: 10268971)
PSNPrescribable
Prescribable Name (PSN):
Burosumab-twza 30 mg in 1 mL Injection
(Atom ID: 10268981)
SYPrescribable
Synonym (SY):
Burosumab-twza 30 mg per 1 mL Injection
(Atom ID: 10268980)
Patient Education
Burosumab-twza Injection
Burosumab-twza injection is used to treat X-linked hypophosphatemia (XLH; an inherited disease where the body doesn't maintain phosphorus and that leads to weak bones) in adults and children 6 months of age and older. It is also used to treat tumor-induced osteomalacia (a tumor that causes a loss of phosphorus in the body that leads to weak bones) that cannot be surgically removed in adults and children 2 years of age and older, Burosumab-twza injection is in a class of medications called fibroblast growth factor 23 (FGF23) blocking antibodies. It works by blocking the action of a certain natural substance in the body which causes the symptoms of XLH.
[Learn More]
* Please review the disclaimer below.